IHC - CD43

IHC – CD43 Test

The IHC CD43 Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CD43 protein expression in tissue samples. CD43 is a cell surface glycoprotein commonly expressed on T-lymphocytes, myeloid cells, plasma cells, and certain B-cell neoplasms, making it an important biomarker in hematopathology and cancer diagnosis.

This test plays a crucial role in identifying and classifying lymphoid and hematologic malignancies, especially when differentiating T-cell lymphomas, leukemias, plasma cell neoplasms, and selected B-cell lymphomas from other cancers.

The IHC CD43 test is commonly used in evaluating:

• T-cell lymphoma
• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)
• Mantle cell lymphoma
• Plasma cell neoplasms
• Myeloid malignancies

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy samples using advanced antibody staining techniques. Expert hematopathologists examine stained tissue microscopically to assess CD43 protein expression and determine tumor lineage.

CD43 is often included as part of a broader immunophenotyping panel alongside markers such as CD3, CD5, CD20, CD23, CD79a, and cyclin D1 for accurate lymphoma classification.

This test is especially valuable when routine histopathology findings are inconclusive or when detailed hematologic cancer classification is required for treatment planning.

Accurate CD43 expression analysis helps oncologists confirm diagnosis, predict prognosis, and guide personalized cancer therapy decisions.

Benefits of the Test

• Detects CD43 protein expression accurately
• Supports lymphoma and leukemia diagnosis
• Helps classify hematologic malignancies
• Assists differential diagnosis
• Improves pathology diagnostic precision
• Supports personalized treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the CD43 IHC Test when:

• Lymphoma is suspected
• Leukemia tissue involvement is being evaluated
• Routine biopsy findings are inconclusive
• Tumor lineage clarification is needed
• Advanced hematologic cancer classification is required
• Differential diagnosis is necessary
• Treatment planning depends on exact diagnosis
• Expert hematopathology confirmation is required

This test improves diagnostic confidence for accurate blood cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology reports
• Relevant clinical and imaging records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the CD43 IHC Test is usually 4–7 working days, depending on staining complexity and interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected lymphoma or leukemia
• Individuals requiring hematologic tumor classification
• Patients with unclear biopsy diagnosis
• Individuals under specialist hematology care
• Oncology patients requiring advanced pathology confirmation
• Patients needing expert immunohistochemistry evaluation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert hematopathology specialists ensure highly accurate CD43 IHC reports for reliable diagnosis and personalized cancer treatment planning.